Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in pulmonary hypertension with HFpEF
2014-003055-60Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary hypertension due to left heart disease (PH-LHD) and heart failure with preserved ejection fraction (HFpEF) comparing Riociguat with Placebo (2 arms). Primary endpoint: Change from baseline in cardiac output at rest. Started Jul 2014; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary hypertension due to left heart disease (PH-LHD)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2014-003055-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003055-60.